open access

Vol 6, No 3 (2010)
Case report
Published online: 2010-08-27
Get Citation

Long-term treatment with trastuzumab of patient with skin metastatic breast cancer — a case report

Aneta L. Zygulska, Krzysztof Krzemieniecki
Onkol. Prak. Klin 2010;6(3):113-115.

open access

Vol 6, No 3 (2010)
CASE REPORTS
Published online: 2010-08-27

Abstract

Trastuzmab is the treatment of choice for HER2-overexpressing metastatic breast cancer. The treatment is well tolerated. Despite the fact that trastuzumab is used commonly, duration of the treatment has not been defined. Case of 46-year old female patient on continuous 5 year trastuzumab was described.
Onkol. Prak. Klin. 2010; 6, 3: 113–115

Abstract

Trastuzmab is the treatment of choice for HER2-overexpressing metastatic breast cancer. The treatment is well tolerated. Despite the fact that trastuzumab is used commonly, duration of the treatment has not been defined. Case of 46-year old female patient on continuous 5 year trastuzumab was described.
Onkol. Prak. Klin. 2010; 6, 3: 113–115
Get Citation

Keywords

metastatic breast cancer; trastuzumab

About this article
Title

Long-term treatment with trastuzumab of patient with skin metastatic breast cancer — a case report

Journal

Oncology in Clinical Practice

Issue

Vol 6, No 3 (2010)

Article type

Case report

Pages

113-115

Published online

2010-08-27

Bibliographic record

Onkol. Prak. Klin 2010;6(3):113-115.

Keywords

metastatic breast cancer
trastuzumab

Authors

Aneta L. Zygulska
Krzysztof Krzemieniecki

References (10)
  1. Jones RL, Smith IE. Efficacy and safety of trastuzumab. Expert Opin Drug Saf. 2004; 3(4): 317–327.
  2. Adamo V, Franchina T, Adamo B, et al. Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study). Ann Oncol. 2007; 18 Suppl 6: vi11–vi15.
  3. Sawaki M, Ito Y, Tada K, et al. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Tumori. 2004; 90(1): 40–43.
  4. Eichbaum MHR, Schneeweiss A, Bastert G. Long-term remission of excessive liver metastases in a breast cancer patient with chronic alcohol abuse using a monotherapy with trastuzumab. Anticancer Drugs. 2005; 16(2): 199–200.
  5. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3): 719–726.
  6. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002; 62(1): 209–243.
  7. Ewer MS, O'Shaughnessy JA. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer. 2007; 7(8): 600–607.
  8. Strevel EL, Siu LL. Cardiovascular toxicity of molecularly targeted agents. Eur J Cancer. 2009; 45 Suppl 1: 318–331.
  9. Shaffer R, Tyldesley S, Rolles M, et al. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol. 2009; 90(1): 122–126.
  10. Beda M, Basso U, Ghiotto C, et al. When should trastuzumab be stopped after achieving complete response in HER2-positive metastatic breast cancer patients? Tumori. 2007; 93(5): 491–492.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl